GE Healthcare: Coronary Artery Disease trials

The registry lists 15 Coronary Artery Disease studies with GE Healthcare as lead sponsor. 2 are open to participants now and 4 have results posted.

Phase 1 1Phase 2 2Phase 3 3Phase 4 4No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary PlaqueNot yet recruitingNCT06186336
• A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric PatientsRecruitingNCT04604782Phase 1/2
• A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing ProcessesCompletedNCT04594941Phase 2Results posted
• An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)CompletedNCT03354273Phase 3Results posted
• Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical CareCompletedNCT00783302Results posted
• Perfusion Imaging and CT -Understanding Relative EfficacyTerminatedNCT00486447Not applicableResults posted
• Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast MediumCompletedNCT03671603
• Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition ApproachesCompletedNCT00381316Phase 4
• A Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCTTerminatedNCT00350506Not applicable
• Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the HeartTerminatedNCT00348608Phase 3
• A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest PainCompletedNCT00348569Not applicable
• Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the HeartTerminatedNCT00335335Phase 3
• Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary AngiographyWithdrawnNCT00335101Phase 4
• Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary AngiographyCompletedNCT00209430Phase 4
• Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)CompletedNCT00209404Phase 4